These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 4537267)

  • 1. The present status of levodopa and future approaches to therapy.
    Mones RJ
    Mt Sinai J Med; 1972; 39(3):279-86. PubMed ID: 4537267
    [No Abstract]   [Full Text] [Related]  

  • 2. Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
    Düby SE; Dahl LK; Cotzias GC
    Trans Assoc Am Physicians; 1971; 84():289-96. PubMed ID: 5164305
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA; Dowson JH; Ahmed R; Chow R; Gillingham FJ
    Confin Neurol; 1972; 34(1):143-8. PubMed ID: 5084388
    [No Abstract]   [Full Text] [Related]  

  • 5. Absence of response to levodopa in Parkinson's disease.
    Mones RJ
    JAMA; 1971 Aug; 217(9):1245. PubMed ID: 5109470
    [No Abstract]   [Full Text] [Related]  

  • 6. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Where do we go from here?
    Clin Pharmacol Ther; 1971; 12(2):408-16. PubMed ID: 5577487
    [No Abstract]   [Full Text] [Related]  

  • 7. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN; Watanabe AM
    Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dopa and decarboxylase inhibitors in Parkinson's disease].
    Pakkenberg H
    Ugeskr Laeger; 1974 Feb; 136(7):377. PubMed ID: 4821980
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa.
    Lancet; 1971 Sep; 2(7723):533. PubMed ID: 4105672
    [No Abstract]   [Full Text] [Related]  

  • 10. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 11. Short- and long-term approaches to the "on-off" phenomenon.
    Papavasiliou PS; Cotzias GC; Mena I
    Adv Neurol; 1974; 5():379-86. PubMed ID: 4440585
    [No Abstract]   [Full Text] [Related]  

  • 12. Levodopa: alterations in behavior.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Clin Pharmacol Ther; 1971; 12(2):383-96. PubMed ID: 4930867
    [No Abstract]   [Full Text] [Related]  

  • 13. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
    Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
    [No Abstract]   [Full Text] [Related]  

  • 14. Physiologic, biochemical, and pathological backgrounds of levodopa and possibilities for the future.
    Hornykiewicz OD
    Neurology; 1970 Dec; 20(12):1-5. PubMed ID: 5531292
    [No Abstract]   [Full Text] [Related]  

  • 15. [Apomorphine in the biochemical concept of Parkinson's tremor].
    Brinkmann R; Strian F
    Nervenarzt; 1974 Sep; 45(9):474-6. PubMed ID: 4437688
    [No Abstract]   [Full Text] [Related]  

  • 16. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007
    [No Abstract]   [Full Text] [Related]  

  • 17. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term treatment of Parkinson's disease with levodopa.
    Campbell JB
    Neurology; 1970 Dec; 20(12):18-22. PubMed ID: 5531291
    [No Abstract]   [Full Text] [Related]  

  • 19. Cerebrospinal homovanillic acid and parkinsonism.
    Miachon S; Dalmaz Y; Cottet-Emard JM; Peyrin L
    Biomedicine; 1974 Jul; 21(7):303-8. PubMed ID: 4433665
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid.
    Klawans HL
    J Neurol Sci; 1971 Dec; 14(4):421-6. PubMed ID: 5125757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.